Jia‐Feng Wu, Yu‐Chun Chiu, Kai‐Chi Chang, Huey‐Ling Chen, Yen‐Hsuan Ni, Hong‐Yuan Hsu, Mei‐Hwei Chang – 21 September 2015 – Hepatitis B e antigen (HBeAg)‐negative hepatitis is a clinical indicator of poor outcome for chronic hepatitis B viral (HBV) infection. This long‐term prospective cohort study aimed to elucidate the predictors of developing HBeAg‐negative hepatitis in chronic HBV‐infected subjects followed from childhood to adulthood. We followed 434 HBeAg‐positive chronic HBV‐infected patients from a median age of 7.22 years (interquartile range 4.31‐10.21 years).

Vivek Vij, Kausar Makki, Vishal Kumar Chorasiya, Gaurav Sood, Ashish Singhal, Puneet Dargan – 21 September 2015 – Biliary complications are regarded as the Achilles' heel of liver transplantation, especially for living donor liver transplantation (LDLT) due to smaller, multiple ducts and difficult ductal anatomy. Overall biliary complications reported in most series are between 10% and 30%. This study describes our modified technique of biliary anastomosis and its effects on incidence of biliary complications.

Anne T. Schneider, Jérémie Gautheron, Frank Tacke, Mihael Vucur, Tom Luedde – 21 September 2015

Evangelos Cholongitas, Nikolaos Antoniadis, Ioannis Goulis, Ioannis Fouzas, Themistoklis Vasiliadis, Evangelos Akriviadis, Vasilios Papanikolaou – 21 September 2015

Keito Yoshimura, Takeshi Okanoue, Hayao Ebise, Tsuyoshi Iwasaki, Masayuki Mizuno, Toshihide Shima, Junji Ichihara, Kazuto Yamazaki – 21 September 2015 – It is important that patients with nonalcoholic steatohepatitis (NASH) are diagnosed and treated early to prevent serious complications, such as liver cirrhosis or hepatocellular carcinoma. However, current methods for NASH diagnosis are invasive given that they rely on liver biopsy, making early diagnosis difficult. In this study, we developed novel noninvasive markers for the diagnosis of NASH and NASH‐related fibrosis.

Anthony Cousien, Viet Chi Tran, Sylvie Deuffic‐Burban, Marie Jauffret‐Roustide, Jean‐Stéphane Dhersin, Yazdan Yazdanpanah – 21 September 2015 – Hepatitis C virus (HCV) seroprevalence remains high in people who inject drug (PWID) populations, often above 60%. Highly effective direct‐acting antiviral (DAA) regimens (90% efficacy) are becoming available for HCV treatment. This therapeutic revolution raises the possibility of eliminating HCV from this population. However, for this, an effective cascade of care is required.

Junichi Togashi, Nobuhisa Akamatsu, Tomohiro Tanaka, Yasuhiko Sugawara, Kunihisa Tsukada, Junichi Kaneko, Junichi Arita, Yoshihiro Sakamoto, Kiyoshi Hasegawa, Norihiro Kokudo – 21 September 2015

Vinzent N. Spetzler, Nicolas Goldaracena, Juan Echiverri, J. Moritz Kaths, Kristine S. Louis, Oyedele A. Adeyi, Paul M. Yip, David R. Grant, Nazia Selzner, Markus Selzner – 21 September 2015 – We developed a novel technique of subnormothermic ex vivo liver perfusion (SNEVLP) for the storage of liver grafts before transplantation. To test the safety of SNEVLP for the nonextended criteria grafts (standard grafts), we compared it to a control group with minimal cold static storage (CS) time. Heart‐beating pig liver retrieval was performed.

Ashok Thorat, Long‐Bin Jeng, Horng‐Ren Yang, Ping‐Chun Li, Ming‐Li Li, Chun‐Chieh Yeh, Te‐Hung Chen, Shih‐Chao Hsu, Kin‐Shing Poon – 21 September 2015 – Outflow reconstruction in living donor liver transplantation (LDLT) is certainly difficult in limited retrohepatic space with using right liver grafts with venous anomalies. Venoplasty of the inferior right hepatic veins (IRHVs) and middle hepatic vein (MHV) reconstruction using synthetic grafts to form a common outflow channel or a second venocaval anastomosis are available options.

Daire O'Shea, John Law, Adrian Egli, Donna Douglas, Gary Lund, Sarah Forester, Joshua Lambert, Mansun Law, Dennis R. Burton, D. L. J. Tyrrell, Michael Houghton, Atul Humar, Norman Kneteman – 21 September 2015 – The anti–hepatitis C virus (HCV) activity of a novel monoclonal antibody (mAb; AR4A) and epigallocatechin gallate (EGCG) were studied in vitro using a HCV cell culture system and in vivo using a humanized liver mouse model capable of supporting HCV replication.